Welcome to AdisInsight

Please enter your official email address

Email Address
Please enter your official email address

Your email address will be used to create a unique number used exclusively to identify you on AdisInsight. Your email address will not be stored or maintained within AdisInsight. Your unique identifier number will be stored in your browser data on your device. This will allow us to know it’s you when you access AdisInsight from your computer, tablet, or phone. To do this you will need to enter your email address the first time to visit AdisInsight from a new device. After that we will recognize you and you will not have to enter your email again unless you have deleted your browser data. We will use your unique identifier number to provide anonymous information to your subscribing organization to allow them to accurately assess the value AdisInsight delivers. For additional information on how we protect your personal information, please refer to our
privacy policy
.

TAK 079

Alternative Names:
TAK079

Latest Information Update: 07 Feb 2019

Price :
$50
*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator
Takeda

Class
Antineoplastics; Antirheumatics; Monoclonal antibodies

Mechanism of Action
CD38 antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

New Molecular Entity
Yes

Highest Development Phases

Phase I/II
Multiple myeloma

Phase I
Systemic lupus erythematosus

No development reported
Rheumatoid arthritis

Most Recent Events

01 Dec 2018
Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in healthy volunteers presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)